KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Total Non-Current Liabilities (2016 - 2025)

Amgen has reported Total Non-Current Liabilities over the past 17 years, most recently at $79.6 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $79.6 billion for Q4 2025, down 4.86% from a year ago — trailing twelve months through Dec 2025 was $79.6 billion (down 4.86% YoY), and the annual figure for FY2025 was $79.6 billion, down 4.86%.
  • Total Non-Current Liabilities for Q4 2025 was $79.6 billion at Amgen, up from $77.9 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AMGN hit a ceiling of $88.6 billion in Q4 2023 and a floor of $45.1 billion in Q2 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $78.8 billion (2025), compared with a mean of $70.6 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 60.96% in 2023 and later fell 8.15% in 2025.
  • Amgen's Total Non-Current Liabilities stood at $54.1 billion in 2021, then grew by 13.06% to $61.2 billion in 2022, then soared by 44.79% to $88.6 billion in 2023, then dropped by 5.62% to $83.6 billion in 2024, then dropped by 4.86% to $79.6 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $79.6 billion (Q4 2025), $77.9 billion (Q3 2025), and $78.0 billion (Q2 2025) per Business Quant data.